47 research outputs found

    Smoothing the Rough Edges: Evaluating Automatically Generated Multi-Lattice Transitions

    Full text link
    Additive manufacturing is advantageous for producing lightweight components while addressing complex design requirements. This capability has been bolstered by the introduction of unit lattice cells and the gradation of those cells. In cases where loading varies throughout a part, it may be beneficial to use multiple, distinct lattice cell types, resulting in multi-lattice structures. In such structures, abrupt transitions between unit cell topologies may cause stress concentrations, making the boundary between unit cell types a primary failure point. Thus, these regions require careful design in order to ensure the overall functionality of the part. Although computational design approaches have been proposed, smooth transition regions are still difficult to achieve, especially between lattices of drastically different topologies. This work demonstrates and assesses a method for using variational autoencoders to automate the creation of transitional lattice cells, examining the factors that contribute to smooth transitions. Through computational experimentation, it was found that the smoothness of transition regions was strongly predicted by how closely the endpoints were in the latent space, whereas the number of transition intervals was not a sole predictor.Comment: 23 Pages, 8 Figure

    Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer

    Get PDF
    Purpose:; Resistance to platinum-based chemotherapy or PARP inhibition in germline; BRCA1; or; BRCA2; mutation carriers may occur through somatic reversion mutations or intragenic deletions that restore BRCA1 or BRCA2 function. We assessed whether; BRCA1/2; reversion mutations could be identified in circulating cell-free DNA (cfDNA) of patients with ovarian or breast cancer previously treated with platinum and/or PARP inhibitors.; Experimental Design:; cfDNA from 24 prospectively accrued patients with germline; BRCA1; or; BRCA2; mutations, including 19 patients with platinum-resistant/refractory ovarian cancer and five patients with platinum and/or PARP inhibitor pretreated metastatic breast cancer, was subjected to massively parallel sequencing targeting all exons of 141 genes and all exons and introns of; BRCA1; and; BRCA2; Functional studies were performed to assess the impact of the putative; BRCA1/2; reversion mutations on BRCA1/2 function.; Results:; Diverse and often polyclonal putative; BRCA1; or; BRCA2; reversion mutations were identified in cfDNA from four patients with ovarian cancer (21%) and from two patients with breast cancer (40%).; BRCA2; reversion mutations were detected in cfDNA prior to PARP inhibitor treatment in a patient with breast cancer who did not respond to treatment and were enriched in plasma samples after PARP inhibitor therapy. Foci formation and immunoprecipitation assays suggest that a subset of the putative reversion mutations restored BRCA1/2 function.; Conclusions:; Putative; BRCA1/2; reversion mutations can be detected by cfDNA sequencing analysis in patients with ovarian and breast cancer. Our findings warrant further investigation of cfDNA sequencing to identify putative; BRCA1/2; reversion mutations and to aid the selection of patients for PARP inhibition therapy.; Clin Cancer Res; 23(21); 6708-20. ©2017 AACR;
    corecore